GNT0004, where are we with this drug-candidate?

Since the presentation of positive results of gene therapy trial for Duchenne muscular dystrophy at Breakthroughs in Muscular Dystrophy organized by ASGCT in Chicago, Genethon’s CEO, Frederic Revah discusses how the drug candidate GNT004 has the potential of becoming best-in-class gene therapy for DMD (Duchenne Muscular Dystrophy).